|
|
|
 |
Search published articles |
 |
|
Showing 5 results for Imod
Dr. B.s. Satish Rao, P. Uma Devi,
Volume 7, Issue 3 (12-2009)
Abstract
Background: Tumor response after multimodality
treatment using combination of radiation,
chemotherapeutic drugs and hyperthermia usually
assessed by parameters such as tumor growth delay,
volume doubling time and regression response. The
study herein was conducted to investigate the usefulness
of micronucleus assay for assessing the
multimodality treatment. Materials and Methods: The
induction of micronuclei (MN) in a transplantable
solid tumor grown in inbred Balb/c mice was
analyzed after treating the tumors with cis-platin
(cDDP), radiation (RT) and hyperthermia (HT). Results:
The MN frequency in tumor was measured at 1, 3, 5
and 7 days of post-treatment. On day 1, all the cDDP
and RT groups, except HT treatment produced
significantly higher MN counts from that of the
untreated tumors. Cis-platin treatment resulted in a
dose-dependent linear increase in the frequency of
MN induction on day one. Combination of radiation
with cDDP or HT, as bimodality treatment further
increased the MN counts. In the tri-modality group
(cDDP+RT+HT) the MN counts were not significantly
higher than the bi -modality treatments, however
there was an immediate tumor shrinkage indicating
the contribution of other forms of cell death.
Although, MN counts were declined after day five
post-treatment, remained significantly higher than the
control on day seven-post treatment in hyperthermia
alone or its combination with RT and RT+ cDDP
groups. Conclusion: Micronucleus assay may be
useful for assessing the post-treatment regression
response of resistant tumors, while monitoring the
response of sensitive tumors the parameters such as
apoptosis and necrosis may also contribute
considerably to tumor cell loss contributing
immediate tumor regression. Iran. J. Radiat. Res.,
2009 7 (3): 119-125
E. Esmati, A. Maddah Safaei, M. Babaei, H. Nosrati, H. Momeni,
Volume 14, Issue 1 (1-2016)
Abstract
Background: Ewing Sarcoma Family of Tumors (ESFTs) is the second most common primary tumors of bone in childhood. The decision regarding the optimal modality for achieving local tumor control remains uncertain. The aim of this study was to report the clinical features and outcome as well as reviewing risk factors in patients. Materials and Methods: This retrospective study included 75 ESFTs patients who were treated at cancer institute between 2004 and 2009. Files of all patients with ESFTs were reviewed retrospectively and we called them for follow up. Specific data were collected with regard to the age at diagnosis, gender, tumor site and size, clinical stage, surgical procedure, plan of radiotherapy and treatment outcome (5-year and median survival). Results: The mean age at diagnosis was 21 that ranged from 1 to 52 years (SD = 9.6). The mean tumor size at diagnosis was 4.8±4.48 cm. The percent of biopsy only, partial and complete resection was 54.7% (41 patients), 6.7% (5 patients) and 37.3% (28 patients) respectively. Radiotherapy was done as definitive treatment or postoperatively (adjuvant) in 46 (61.3%) and 16 (21.4%) patients respectively. Overall 5 year survival was 24% and median survival for patients with and without metastases was 21±17 and 75±10 months. Conclusion: Presence of metastases, age at diagnosis, positive surgical margin and tumor size were the prognostic factors that influenced outcome of patients. This study suggests that radiation therapy is an acceptable local treatment modality in patients with Ewing sarcoma family.
A. Shakeri-Boroujeni, Dr. H. Mozdarani, M. Mahmmoudzadeh, F. Faeghi,
Volume 14, Issue 3 (7-2016)
Abstract
Background: Although numerous natural or synthetic drugs have been tested for their radioprotective capacity, yet no suitable drug has been introduced for routine clinical use. In this study the radioprotective effect of "a new herbal immunomodulator" commercially known as IMOD, specifically made to decrease the side effects of HIV virus, was investigated on mouse bone marrow cells. Materials and Methods: Female NMRI mice (in a group of five) were exposed to 2 Gy gamma radiation following three days of intravenously injection (IV) of IMOD at various doses. Mice were sacrificed 48 and 72 h after irradiation. Bone marrow was flushed and slides for bone marrow smears were prepared according to standard method. After staining slides in May Grunwald and Giemsa, polychromatic erythrocytes (PCE) and normochromatic erythrocytes (NCE) were scored for presence of micronucleus (MN). Results: The results showed that gamma irradiation increased the frequency of micronuclei dramatically and excreted cytotoxic effect of cell proliferation. Injection of various doses of IMOD before irradiation however, led to a considerable reduction in the frequency of micronuclei in bone marrow erythrocytes as well as cellular toxicity. Conclusion: Results indicated radioprotective capability of IMOD with a dose reduction factor (DRF) of about 2.3 at a dose of 20 mg/kg body weight. The considerably high DRF might be indicative that IMOD besides being an immunomodulator might also posses’ antioxidant property.
W. Wang, D. Feng, Q. Song, W. Sun, D. Zhang, M. Li, K. Li, H. Chen, F. Li,
Volume 22, Issue 2 (4-2024)
Abstract
Background: Multimodal medical imaging plays a key role in the diagnosis and differential diagnosis of myocarditis, enabling a comprehensive assessment of cardiac structure and function. Materials and Methods: We used multimodal medical imaging technology to diagnose and differential diagnose patients with myocarditis, and analyzed the patient data in detail. Results: Multimodal medical imaging techniques provide a wealth of information to help distinguish myocarditis from other heart diseases. Conclusion: Multimodal medical imaging is of great value in the diagnosis and differential diagnosis of myocarditis, but there are still some challenges and limitations in its application.
M.d. J. Zhai, J. Li,
Volume 23, Issue 2 (5-2025)
Abstract
Background: Background: While conventional ultrasound (US) remains the first-line diagnostic tool, its limitations in distinguishing benign from malignant nodules necessitate exploring complementary techniques. This study aimed to evaluate the potential of integrating contrast-enhanced ultrasound (CEUS) and ultrasound elastography (UE) alongside conventional US to improve diagnostic accuracy compared to individual modalities. Materials and Methods: This retrospective analysis was conducted at Tangshan people's Hospital. We enrolled 180 consecutive patients diagnosed with thyroid nodules between January 2021 and December 2022. All participants underwent comprehensive ultrasound examinations comprising conventional US, CEUS, and UE. Fine-needle aspiration biopsy (FNAB) or surgical specimens were the gold standard for definitive diagnosis. Patients with inconclusive diagnoses or incomplete examinations were excluded. Results: Conventional US (ACR TI-RADS) achieved an AUC of 0.802, excelling in detecting suspicious features but suffering from inherent subjectivity. CEUS, with an AUC of 0.854 and a remarkable sensitivity of 95.29%, captured specific malignant patterns like centripetal enhancement and uneven distribution, but its reliance on contrast limited its applicability. UE provided an area under the curve (AUC) of 0.845 and valuable information about tissue stiffness, but its efficacy was influenced by nodule size and location. However, the true strength emerged when combining all three modalities. Multimodal ultrasound yielded an impressive AUC of 0.958 and a sensitivity of 91.76%, significantly surpassing individual performances. Conclusion: Our findings demonstrate that multimodal ultrasound, integrating conventional US, CEUS, and UE, significantly outperforms individual modalities in diagnosing thyroid nodules. Further research is warranted to refine and optimize this promising diagnostic strategy to benefit patients with thyroid nodules.
|
|
